Chimerex to supply unapproved drug to try to save dying boy


Chimerix (CMRX +10.5%) has agreed to provide its Brincidofovir (CMX001) treatment to a seven-year-old boy who is dying from an adenovirus infection after his immune system was weakened by a bone-marrow transplant.

Chimerex had initially refused to supply the drug, as it's not approved, but caved in after huge pressure in the media.

The company will make the boy, named Josh Hardy, the first patient in a 20-patient pilot trial, with the FDA saying it will help the firm design a Phase III study that could be launched as a continuation of the pilot. (PR)

This was corrected on 04/09/2014 at 09:39 AM.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs